TY - JOUR
T1 - A potential therapeutic target for FLT3-ITD AML
T2 - PIM1 kinase
AU - Fathi, Amir T.
AU - Arowojolu, Omotayo
AU - Swinnen, Ian
AU - Sato, Takashi
AU - Rajkhowa, Trivikram
AU - Small, Donald
AU - Marmsater, Fredrik
AU - Robinson, John E.
AU - Gross, Stefan David
AU - Martinson, Matthew
AU - Allen, Shelley
AU - Kallan, Nicholas C.
AU - Levis, Mark
N1 - Funding Information:
This work was supported by grants from the NCI (NCI Leukemia SPORE P50 CA100632-06 , R01 CA128864 ) and the American Society of Clinical Oncology (ML). Mark Levis is a Clinical Scholar of the Leukemia and Lymphoma Society.
PY - 2012/2
Y1 - 2012/2
N2 - Patients with acute myeloid leukemia (AML) and a FLT3 internal tandem duplication (ITD) mutation have a poor prognosis, and FLT3 inhibitors are now under clinical investigation. PIM1, a serine/threonine kinase, is up-regulated in FLT3-ITD AML and may be involved in FLT3-mediated leukemogenesis. We employed a PIM1 inhibitor, AR00459339 (Array Biopharma Inc.), to investigate the effect of PIM1 inhibition in FLT3-mutant AML. Like FLT3 inhibitors, AR00459339 was preferentially cytotoxic to FLT3-ITD cells, as demonstrated in the MV4-11, Molm-14, and TF/ITD cell lines, as well as 12 FLT3-ITD primary samples. Unlike FLT3 inhibitors, AR00459339 did not suppress phosphorylation of FLT3, but did promote the de-phosphorylation of downstream FLT3 targets, STAT5, AKT, and BAD. Combining AR00459339 with a FLT3 inhibitor resulted in additive to mildly synergistic cytotoxic effects. AR00459339 was cytotoxic to FLT3-ITD samples from patients with secondary resistance to FLT3 inhibitors, suggesting a novel benefit to combining these agents. We conclude that PIM1 appears to be closely associated with FLT3 signaling, and that inhibition of PIM1 may hold therapeutic promise, either as monotherapy, or by overcoming resistance to FLT3 inhibitors.
AB - Patients with acute myeloid leukemia (AML) and a FLT3 internal tandem duplication (ITD) mutation have a poor prognosis, and FLT3 inhibitors are now under clinical investigation. PIM1, a serine/threonine kinase, is up-regulated in FLT3-ITD AML and may be involved in FLT3-mediated leukemogenesis. We employed a PIM1 inhibitor, AR00459339 (Array Biopharma Inc.), to investigate the effect of PIM1 inhibition in FLT3-mutant AML. Like FLT3 inhibitors, AR00459339 was preferentially cytotoxic to FLT3-ITD cells, as demonstrated in the MV4-11, Molm-14, and TF/ITD cell lines, as well as 12 FLT3-ITD primary samples. Unlike FLT3 inhibitors, AR00459339 did not suppress phosphorylation of FLT3, but did promote the de-phosphorylation of downstream FLT3 targets, STAT5, AKT, and BAD. Combining AR00459339 with a FLT3 inhibitor resulted in additive to mildly synergistic cytotoxic effects. AR00459339 was cytotoxic to FLT3-ITD samples from patients with secondary resistance to FLT3 inhibitors, suggesting a novel benefit to combining these agents. We conclude that PIM1 appears to be closely associated with FLT3 signaling, and that inhibition of PIM1 may hold therapeutic promise, either as monotherapy, or by overcoming resistance to FLT3 inhibitors.
KW - Acute myeloid leukemia
KW - FLT3
KW - Internal tandem duplication
KW - PIM1 kinase
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84855206895&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855206895&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2011.07.011
DO - 10.1016/j.leukres.2011.07.011
M3 - Article
C2 - 21802138
AN - SCOPUS:84855206895
SN - 0145-2126
VL - 36
SP - 224
EP - 231
JO - Leukemia Research
JF - Leukemia Research
IS - 2
ER -